James began creating computer art several years ago using the Fractal Design Painter programs, Corel Draw and Photoshop. He studied design at Sacred Heart University, Fairfield University and the Creative Art Workshop. His work appeared in the “National Association of Desktop Publishers Journal” and “Computer Graphics World” magazine.
Jose’s artwork was created in an MDA sponsored children’s art workshop held January 23, 1993, at the Arizona State University Art Building in Tempe. It has been shown in several exhibits and was featured in an MDA holiday card.
Complete and extremely encouraging findings from a phase 1b-2 trial of eteplirsen (AVI-4658), an exon skipping drug in development to treat a portion of the Duchenne muscular dystrophy (DMD) population, show the compound is safe and well-tolerated, and that it can significantly increase production of the needed dystrophin protein in recipients without eliciting an unwanted immune response.
A one-year, MDA-supported study comparing a weekend-only prednisone treatment schedule with a daily prednisone schedule in boys with Duchenne muscular dystrophy (DMD) has found that the two treatment regimens provide about the same benefits and have approximately the same side-effect profile.
In January 2005, the American Academy of Neurology (AAN) released its long-awaited report on the use of corticosteroids (prednisone or deflazacort) inDuchenne muscular dystrophy (DMD). The report is also published in the Jan. 11 issue of Neurology. It finds that corticosteroids are beneficial in DMD, but that some drawbacks to their use must be considered.
MDA has funded Duchenne muscular dystrophy research since 1950, and has paid for more research into this disease than any nongovernmental agency. It also provides the most comprehensive services program of any nonprofit organization in the country.